Literature DB >> 17851548

Myocarditis following adeno-associated viral gene expression of human soluble TNF receptor (TNFRII-Fc) in baboon hearts.

C F McTiernan1, M A Mathier, X Zhu, X Xiao, E Klein, C H Swan, H Mehdi, G Gibson, A M Trichel, J C Glorioso, A M Feldman, K R McCurry, B London.   

Abstract

Sequestration of tumor necrosis factor-alpha (TNFalpha) by TNF-receptor immunoglobulin G (IgG)-Fc fusion proteins can limit heart failure progression in rodent models. In this study we directly injected an adeno-associated viruses (AAV)-2 construct encoding a human TNF receptor II IgG-Fc fusion protein (AAV-TNFRII-Fc) into healthy baboon hearts and assessed virally encoded gene expression and clinical response. Adult baboons received direct cardiac injections of AAV-TNFRII-Fc ( approximately 5 x 10(12) viral/genomes/baboon) or an equivalent dose of AAV-2 empty capsids, and were analyzed after 5 or 12 weeks. Viral genomes were restricted to the myocardium, and routine analyses (blood cell counts, clinical chemistries) remained unremarkable. Echocardiograms were unchanged but electrocardiograms revealed marked ST- and T-wave changes consistent with myocarditis only in baboons receiving AAV-TNFRII-Fc. TNFRII serum levels peaked at approximately 3 times the baseline levels at 1-2 weeks postinjection and subsequently declined to baseline levels. TNFRII-Fc protein and transcripts were detected in the heart at harvest. After AAV injection, anti-AAV-2 antibody levels increased in all baboons, while anti-TNFRII-Fc could not be detected. Baboons that received AAV-TNFRII-Fc developed myocardial infiltrates including CD8+ cells. Thus, a cellular immune response to cardiac delivery of AAV encoding foreign proteins may be an important consideration for AAV-based cardiac gene therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17851548     DOI: 10.1038/sj.gt.3303020

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  16 in total

Review 1.  Nanoscale strategies: treatment for peripheral vascular disease and critical limb ischemia.

Authors:  Chengyi Tu; Subhamoy Das; Aaron B Baker; Janeta Zoldan; Laura J Suggs
Journal:  ACS Nano       Date:  2015-04-10       Impact factor: 15.881

Review 2.  Gene therapy for heart failure.

Authors:  Lisa Tilemann; Kiyotake Ishikawa; Thomas Weber; Roger J Hajjar
Journal:  Circ Res       Date:  2012-03-02       Impact factor: 17.367

3.  Neuromuscular Gene Therapy: Catching the Wave of Positive Early Studies Is Expected to Crest in Product Approvals.

Authors:  Barry J Byrne
Journal:  Mol Ther       Date:  2019-09-23       Impact factor: 11.454

Review 4.  AAV vectors for cardiac gene transfer: experimental tools and clinical opportunities.

Authors:  Christina A Pacak; Barry J Byrne
Journal:  Mol Ther       Date:  2011-07-26       Impact factor: 11.454

Review 5.  Promise of adeno-associated virus as a gene therapy vector for cardiovascular diseases.

Authors:  Abesh Bera; Dwaipayan Sen
Journal:  Heart Fail Rev       Date:  2017-11       Impact factor: 4.214

Review 6.  Novel polymer carriers and gene constructs for treatment of myocardial ischemia and infarction.

Authors:  James W Yockman; Andrew Kastenmeier; Harold M Erickson; Jonathan G Brumbach; Matthew G Whitten; Aida Albanil; Dean Y Li; Sung Wan Kim; David A Bull
Journal:  J Control Release       Date:  2008-07-06       Impact factor: 9.776

7.  Percutaneous transendocardial delivery of self-complementary adeno-associated virus 6 achieves global cardiac gene transfer in canines.

Authors:  Lawrence T Bish; Meg M Sleeper; Benjamin Brainard; Stephen Cole; Nicholas Russell; Elanor Withnall; Jason Arndt; Caryn Reynolds; Ellen Davison; Julio Sanmiguel; Di Wu; Guangping Gao; James M Wilson; H L Sweeney
Journal:  Mol Ther       Date:  2008-09-23       Impact factor: 11.454

8.  Systems approach to understanding electromechanical activity in the human heart: a national heart, lung, and blood institute workshop summary.

Authors:  Yoram Rudy; Michael J Ackerman; Donald M Bers; Colleen E Clancy; Steven R Houser; Barry London; Andrew D McCulloch; Dennis A Przywara; Randall L Rasmusson; R John Solaro; Natalia A Trayanova; David R Van Wagoner; András Varró; James N Weiss; David A Lathrop
Journal:  Circulation       Date:  2008-09-09       Impact factor: 29.690

Review 9.  An emerging adeno-associated viral vector pipeline for cardiac gene therapy.

Authors:  Aravind Asokan; R Jude Samulski
Journal:  Hum Gene Ther       Date:  2013-11       Impact factor: 5.695

10.  Subretinal delivery of adeno-associated virus serotype 2 results in minimal immune responses that allow repeat vector administration in immunocompetent mice.

Authors:  Susie E Barker; Cathryn A Broderick; Scott J Robbie; Yanai Duran; Mythili Natkunarajah; Prateek Buch; Kamaljit S Balaggan; Robert E MacLaren; James W B Bainbridge; Alexander J Smith; Robin R Ali
Journal:  J Gene Med       Date:  2009-06       Impact factor: 4.565

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.